New evidence reveals the gene therapy from Astellas that led to four patient deaths may also be very effective

Japanese pharma has done a dozen therapeutics deals so far this year, with at least seven showcasing how it’s building within defined focus areas

Kate’s platform for increasing the potency and decreasing the liver tox of AAVs has attracted Astellas as a partner

BioCentury’s roundup of translational news

Plus: Asher’s $108M B round, Mesoblast denial, Astellas’ liver tox concerns and more

Chi-Med’s surufatinib approved in ChinaChina’s National Medical Products Administration (NMPA) approved an NDA from Hutchison China MediTech Ltd. (NASDAQ:HCM; LSE:HCM) for Sulanda

Astellas gained AT132, Audentes’ lead program, via its $3B acquisition of the biotech last year